Highest-materiality recent filing
Damora Therapeutics completes redomestication from Delaware to Cayman Islands
Redomestication effective July 16, 2026; each common share converted 1:1 into ordinary shares of Cayman company.
Elected Michael Landsittel and Cameron Turtle as Class III directors; ~51.4M votes for each, 29K withheld.
Effective May 1, 2026, Lori Firmani will cease serving as CFO of Damora Therapeutics.
Damora Therapeutics dismisses EY Denmark auditor, appoints EY US
Audit Committee dismissed EY Denmark on April 17, 2026; EY US appointed same day.
Damora Therapeutics appoints Jennifer Jarrett as CEO, adds two directors, names chairman
Jennifer Jarrett appointed President and CEO, effective March 30, 2026; also joins board.
Galecto rebrands as Damora Therapeutics (DMRA); $535M cash; DMR-001 IND mid-2026
Name changed from Galecto to Damora Therapeutics; trades on Nasdaq as DMRA from March 10, 2026.
Galecto raises $295.9M in equity offering; funds Phase 3 of DMR-001
Offering of 14,473,685 shares at $19.00 each; underwriters' option for 2,171,052 additional shares exercised in full.
CEO Hans T. Schambye departs effective Feb 10, 2026; COO Sherwin Sattarzadeh appointed interim principal executive officer.
Filed under Item 7.01 with a corporate presentation (January 2026) as Exhibit 99.1.
Galecto appoints Sherwin Sattarzadeh as COO; issues warrant to Paramora
Sherwin Sattarzadeh appointed COO effective Jan 5, 2026; base salary $540,000, target bonus 40%.
Galecto corrects Series C Preferred Stock authorization from 43,855 to 43,882 shares
Filed Certificate of Correction on Dec 5, 2025 to fix inadvertent error in Series C Preferred Stock designation.
Galecto acquires Damora, raises ~$285M PIPE, appoints Fairmount-affiliated directors
Galecto acquired Damora Therapeutics; issued 265,309 common shares, 16,366 Series B and 4,241 Series C preferred shares to Damora stockholders.
Carl Goldfischer and David Shapiro elected as Class II directors with 219,253 and 226,360 votes for; 435,515 broker non-votes.
Galecto appoints Dr. Amy Wechsler to Board of Directors effective October 11, 2024
Board expanded to seven members; Wechsler appointed as Class I director with term through 2027 annual meeting.
Galecto acquires global rights to BRM-1420 dual ENL-YEATS/FLT3 inhibitor for AML
Galecto issued 62,594 common shares and 160.562 Series A convertible preferred shares (convertible into 160,562 common) to Bridge Medicines.
Galecto regains Nasdaq minimum bid price compliance; matter closed
Received Nasdaq Staff letter confirming compliance with Rule 5550(a)(2) based on bid price >= $1.00 from Aug 30 to Sep 13, 2024.
Galecto completes 1-for-25 reverse stock split; post-split shares at 1,248,266
Reverse stock split effective August 29, 2024; every 25 shares converted to 1 share.
Galecto effectuates 1-for-25 reverse stock split effective August 29, 2024
Stockholders approved reverse split at June 20 special meeting; board set ratio at 1-for-25.
Galecto shareholders approve reverse stock split and elect Anne Prener to board
Director Anne Prener elected with 10,651,770 for, 711,618 withheld; 5,840,793 broker non-votes.
Galecto transfers to Nasdaq Capital Market; granted 180-day extension for bid price compliance
Transferred listing from Nasdaq Global Select to Nasdaq Capital Market effective March 22, 2024.
6 of 10 evaluable myelofibrosis patients on GB2064 monotherapy ≥6 months had ≥1-grade reduction in bone marrow collagen fibrosis.
Galecto reports 60% response rate in GALLANT-1 part A; halts Part B to focus on liver disease
Three of five NSCLC patients at 100 mg GB1211 BID plus atezolizumab achieved partial response vs. 22–38% for atezolizumab monotherapy.
Galecto receives Nasdaq deficiency notice for bid price below $1.00; 180 days to cure
Nasdaq notified Galecto that common stock bid price closed below $1.00 for 30 consecutive business days.
Galecto explores strategic alternatives; cuts workforce 70%, CMO out
Workforce reduction of ~29 employees (~70% of headcount) approved Sept 20, 2023.
Galecto's Phase 2b GALACTIC-1 trial misses primary endpoint; GB0139 discontinued
GALACTIC-1 trial did not meet primary endpoint of FVC decline; change from baseline -316.6 mL vs -127.4 mL (placebo).
Galecto stockholders elect three Class III directors and ratify EY as auditor at 2023 annual meeting
Elected Jayson Dallas, Amit Munshi, and Hans Schambye as Class III directors with 9.9M, 10.5M, and 10.5M votes for, respectively.
Galecto discloses SVB exposure under $1.5M; no material impact expected
FDIC took control of Silicon Valley Bank on March 10, 2023 due to liquidity concerns.
Galecto reports $66M cash as of Dec 31, 2022; updates corporate presentation
Cash, cash equivalents, and investments of approx. $66M as of Dec. 31, 2022.
Galecto GB1211 reduces signs of liver impairment in GULLIVER-2 trial; data presented at AASLD
GB1211 well-tolerated with predictable PK; showed reductions in liver enzymes and FibroScan, indicating decreased inflammation and steatosis.
Galecto reports GB2064 reduces bone marrow fibrosis in 4 of 5 evaluable myelofibrosis patients
Four of five evaluable patients on GB2064 achieved ≥1-grade reduction in collagen fibrosis over 6 months.
Galecto stockholders elect two Class II directors and ratify auditor at 2022 annual meeting
Carl Goldfischer, M.D. elected with 11,025,408 votes for; David Shapiro, M.D. with 11,050,440 votes for.
Galecto forms R&D Committee, boosts non-executive Chair option grant to 36,000 shares
R&D Committee established; members receive $7,500/yr retainer, Chair gets additional $7,500/yr.
Study met primary safety endpoint: no treatment-related adverse events in 20 GB0139 patients.
Galecto files updated corporate presentation for January 2022 investor meetings
Presentation titled 'First-in-class small-molecule anti-fibrotic and anti-cancer agents'.
Galecto adopts executive Separation Benefits Plan with tiered severance for C-Level officers
Plan covers CEO, CFO, COO, CMO, General Counsel and other designated employees.
the Board appointed Brian Burkavage, the Company’s current Senior Vice President, Finance, to serve as the Company’s principal financial officer and principal accounting officer, effective as of the Effective Time.
the Board of Directors (the “Board”) of Damora Therapeutics, Inc. (the “Company”) determined that, effective as of May 1, 2026 (the “Effective Time”), Lori Firmani would cease serving as the Company’s Chief Financial Officer.
appointed Amy Wechsler to join the Board, effective as of October 11, 2024.
on September 21, 2023, the Company informed Bertil Lindmark, M.D., the Company’s Chief Medical Officer, that his position will be eliminated and that his duties will be assumed by Hans Schambye, M.D., Ph.D., the Company’s Chief Executive Officer.
Max materiality 0.90 · Median 0.55 · Most common event other_material